目的 评价Turbohawk定向斑块切除系统联合药物涂层球囊在下肢动脉硬化闭塞症中临床应用价值。方法 对于术前超声以及下肢动脉CTA检查诊断为下肢动脉硬化闭塞症的8例患者,行Turbohawk斑块旋切以及药物涂层球囊治疗,术后行常规抗凝治疗,定期行彩超复查。结果 8例患者下肢动脉均全部再通成功,技术成功率为100%,术后缺血症状明显改善,术后平均踝肱指数为0.78±0.06,高于术前的0.31±0.12(P<0.05)。住院期间无并发症发生,随访3～18个月,患者保肢均获得成功。结论 Turbohawk定向机械旋切系统联合药物涂层球囊治疗下肢动脉硬化闭塞症,具有创伤小、疗效好以及安全性高等优点,值得临床推广使用。

Objective To evaluate clinical application of using Turbohawk atherectomy device in combination with drug-coated balloon in treatment of atreriosclerosis obliterans in lower extremity. Methods Turbohawk atherectomy device and DCB was performed in 8 patiments with atreriosclerosis obliterans in lower extremity. All patients were diagnosed by ultrasound and CTA. Routine anticoagulation drugs were used after the operation. Follow-up was carried out with color Doppler ultrasound. Results Revascularization was gained in 8 patients. The technically successful rate was 100% and ischemic symptoms relieved significantly immediately after the operation. The post-operative ankle brachinal index(ABI) was 0.78±0.06,which was higher than that of before operation(0.31±0.12). No obvious complications occurred after operation. The follow-up range was 3~18 months and limbs were salvaged successfully. Conclusion With minimal invasive, safe and few complications, Turbohawk atherectomy device in combination with drug-coated balloon is proved to be a very effective treatment atreriosclerosis obliterans in lower extremity and it is worth to popularize.

目的 探讨妈富隆用于治疗围绝经期功血的临床效果。方法 选择年龄40~53岁的出现围绝经期功血的育龄妇女100例。采用盲选法随机分为观察组和对照组,每组各50例。观察组诊刮后第5天开始口服妈富隆,开始每次服1片,每8 h服1次,血止后每3天递减1/3剂量,至维持量1片/天,共计21天,停药后撤退性出血的第5天开始服下周期的药;对照组诊刮后第15天开始口服醋酸甲羟孕酮片,10 mg/天,连服10 天停药后撤退性出血的第15天开始服下周期的药;两组各连服3个周期。结果 观察组服药后阴道流血控制时间和完全止血时间明显短于对照组,在治疗效果方面,观察组总有效率90%,对照组48%,观察组疗效优于对照组。结论 妈富隆治疗围绝经期功血的效果优于孕激素后半周期治疗围绝经期功血的效果,临床上值得推广。

Objective To investigate the clinical effect of Marvelonon perimenopausal dysfunctional uterine bleeding. Methods Select the age 40-53 year old appearance ofperimenopausal dysfunctional uterine bleeding of 100 women of childbearing age. The blind were randomly divided into the observation group and the control groupmethod, 50 cases in each group. The observation group and curettage fifth days after the start of Marvelon, begin to take 1 tablets eachtime, every 8 h 1 times, after the cessation of blood every 3 days and decreasing 1/3 dose,to maintain the volume of 1 pieces of/d, a total of 21 days, fifth days after stopping drug withdrawal bleedingbegan to take periodic drug; control group and curettagefifteenth days after the start of oral medroxyprogesterone acetate tablets, 10 mg/d, and even served fifteenth daysafter withdrawal of 10d. withdrawal bleeding began to takeperiodic drug; two of each suit 3 cycle group. Results The observation group after taking the vaginal bleedingcontrol time and complete hemostasis time significantly shorter than the control group, in treatment effect, total effective rate of observation group 90%, contrast group48%, observation group was significantly better than the control group. Conclusion Conclusion Marvelon on perimenopausal dysfunctional uterine bleeding effect is better than the second half cycleof progesterone treatment of perimenopausal dysfunctional uterine bleeding effect, is worth popularizingin clinic.